NEUPRO

Peak

rotigotine

NDATRANSDERMALFILM, EXTENDED RELEASE
Approved
May 2007
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20

Mechanism of Action

Dopamine Agonists

Pharmacologic Class:

Nonergot Dopamine Agonist

Clinical Trials (5)

NCT03992196Phase 3Terminated

A Follow-up Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome

Started Dec 2019
10 enrolled
Restless Legs Syndrome
NCT04183634Phase 1Terminated

An Open, Randomised, Single Dose, 2-period, 2-sequence Crossover Adhesion Study of Two Different Transdermal Patches Containing Rotigotine.

Started Dec 2019
31 enrolled
Parkinson Disease
NCT03728933Phase 3Terminated

A Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome of Unknown Cause

Started Dec 2018
23 enrolled
Restless Legs Syndrome
NCT03098368Phase 4Unknown

Rotigotine Effect on Nocturnal Hypokinesia Compares to Placebo Control: A Quantitative Assessment by Wearable Sensors

Started Sep 2016
40 enrolled
Nocturnal Hypokinesia
NCT02227355N/ACompleted

Evaluating the Effectiveness of Neupro® (Rotigotine) and L-dopa Combination Therapy in Patients With Parkinson's Disease

Started Sep 2014
195 enrolled
Idiopathic Parkinson's Disease

Loss of Exclusivity

LOE Date
Mar 1, 2032
72 months away
Patent Expiry
Mar 1, 2032

Patent Records (4)

Patent #ExpiryTypeUse Code
8246979
Sep 1, 2027
Product
U-1273
10130589
Dec 22, 2030
Product
10350174
Dec 22, 2030
Product
9925150
Mar 1, 2032
Product